Product Images Doxazosin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Doxazosin NDC 50090-0704 by A-s Medication Solutions, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

doxazosin-structure.jpg - doxazosin structure

doxazosin-structure.jpg - doxazosin structure

figure1.jpg - figure1

figure1.jpg - figure1

Label Image - lbl500900701

Label Image - lbl500900701

Not available. The text is too short and incomplete to generate a useful description.*

Label Image - lbl500900704

Label Image - lbl500900704

Product No. 5169-0 is a box of 30 tablets with a Lo7' logo and printed with the text "BOXAZOSTN 26". No further information is available.*

Label Image - lbl500900706

Label Image - lbl500900706

Label Image - lbl500900734

Label Image - lbl500900734

This appears to be a medication label or box. The product name may be "BoxazosTH" and it comes in a package with 36 tablets. It also appears to have a dosage of 8 mg.*

table3.jpg - table3

table3.jpg - table3

This is a summary of the effectiveness data from placebo-controlled trials on the maximum flow rate and symptom scoreĀ® rate (mL/sec). The table shows mean baseline change for placebo and doxazosin-treated patients. The efficacy was measured using the AUA questionnaire and the Modified Boyarsky Questionnaire, with a range of 0-30 and 7-39, respectively. Change is measured at the endpoint or fixed-dose efficacy phase, with varying hours post-dose for each study. Study 1 was conducted in hypertensives with BPH, and 35 patients received a dose of 8 mg doxazosin. The results show significant improvement in symptom score and maximum flow rate for doxazosin compared to placebo. The table also shows that in Study 2, titration to a fixed dose of doxazosin (2 mg or 4 mg) for 14 weeks resulted in a significant improvement in symptom score and maximum flow rate compared to placebo.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.